Alger Health Sciences Fund Class Z (AHSZX)

Fund Assets	75.36M
Expense Ratio	0.76%
Min. Investment	$500,000
Turnover	289.28%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	n/a

Previous Close	31.09
YTD Return	31.25%
1-Year Return	58.07%
5-Year Return	3.09%
52-Week Low	19.71
52-Week High	31.11
Beta (5Y)	0.76
Holdings	56
Inception Date	May 28, 2015

About AHSZX

Alger Health Sciences Fund Class Z is an actively managed mutual fund focused on the health sciences sector. The fund seeks long-term capital appreciation by investing at least 80% of its net assets in equity securities of companies operating within the healthcare industry, including drug manufacturers, biotechnology firms, medical device companies, and related healthcare services. By emphasizing growth stocks across a range of market capitalizations, the fund aims to capture opportunities from innovation and advances in medical technology and healthcare delivery. Alger Health Sciences Fund Class Z leverages fundamental research to identify companies with strong growth potential and has maintained a cost structure that is competitive within its peer group. As a sector equity fund, it plays a specialized role in the financial market, allowing investors to target exposure to the dynamic and evolving healthcare industry, which is often influenced by trends in medical breakthroughs, demographics, and regulatory changes.

• Fund Family: Alger
• Category: Health
• Performance Rating: Average
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: AHSZX
• Share Class: Class Z
• Index: S&P 500 TR

Performance

AHSZX had a total return of 58.07% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.55%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
AHSAX	Class A	1.17%
AHSCX	Class C	1.96%

Top 10 Holdings

37.50% of assets

Name	Symbol	Weight
Impulse Dynamics Ireland Series F-3	n/a	4.90%
Bruker Corporation	BRKR	4.56%
Teva Pharmaceutical Industries Limited	TEVA	4.55%
Merck & Co., Inc.	MRK	4.40%
CVS Health Corporation	CVS	3.46%
Eli Lilly and Company	LLY	3.44%
Novo Nordisk A/S	NVO	3.20%
Forte Biosciences, Inc.	FBRX	3.02%
Welltower Inc.	WELL	3.01%
Guardant Health, Inc.	GH	2.96%

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Aug 27, 2026

Data Sources Report a data error